Omeros (NASDAQ:OMER) Stock Rating Lowered by StockNews.com

Omeros (NASDAQ:OMER) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday.

Omeros Stock Down 1.6 %

Shares of Omeros stock opened at $4.19 on Tuesday. The company has a market cap of $242.81 million, a price-to-earnings ratio of -1.83 and a beta of 1.47. The company’s 50 day moving average is $4.02 and its 200 day moving average is $4.05. Omeros has a twelve month low of $1.38 and a twelve month high of $5.68.

Institutional Trading of Omeros

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OMER. BNP Paribas Financial Markets increased its holdings in Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 7,016 shares during the last quarter. SPC Financial Inc. purchased a new stake in Omeros during the third quarter valued at approximately $77,000. SG Americas Securities LLC purchased a new stake in Omeros during the third quarter valued at approximately $80,000. Oppenheimer & Co. Inc. purchased a new stake in Omeros during the first quarter valued at approximately $85,000. Finally, Comerica Bank increased its holdings in Omeros by 20.0% during the first quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 5,000 shares during the last quarter. 48.79% of the stock is owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.